Drug Trial Radar · NCT02577406
An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation
Last checked: Nov 19, 2026Latest source record: May 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
319
Actual
Start
Dec 30, 2015
Primary completion
Mar 17, 2020
Study completion Mar 25, 2024
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Oct 16, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an international, multicenter, open-label, randomized, Phase 3 study comparing the efficacy and safety of AG-221 versus conventional care regimens (CCRs) in subjects 60 years or older with acute myeloid leukemia (AML) refractory to or relapsed after second- or third-line AML therapy and positive for an isocitrate dehydrogenase (IDH2) mutation.
Conditions
- Leukemia, Myeloid
- Isocitrate Dehydrogenase
Interventions
AG-221Drug
Continuous 28-day cycles of AG 221 100 mg orally (PO) once a day (QD) for 28 days
BSCOther
Best supportive care includes, hydroxyurea for leukocytosis and/or differentiation-like syndrome, anti-infectives, analgesics, antiemetics, antipyretics, transfusions and nutritional support
AzacitidineDrug
continuous 28-day cycles of azacitidine 75 mg/m2/day SC for 7 days, plus BSC
Low-dose cytarabine (LDAC)Drug
continuous 28-day cycles of cytarabine 20 mg SC twice a day (BID) for 10 days, plus BSC
Intermediate-dose cytarabine (IDAC)Drug
28-day cycles of cytarabine 0.5 to 1.5 g/m2/day IV for 3 to 6 days, per standard institutional practice, plus BSC; only BSC given after IDAC therapy concludes per standard institutional practice
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: From randomization to death due to any cause (up to approximately 49 months)
Locations
93 sites in 18 countries. Site status is shown where the registry gives one.
Local Institution - 121
Miami, Florida
University of Florida Health Cancer Center at Orlando Health
Orlando, Florida
Local Institution - 111
Chicago, Illinois
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey
Roswell Park Cancer Institute
Buffalo, New York
Local Institution - 128
New York, New York
Strong Health System
Rochester, New York
Montefiore Medical Center Albert Einstein Cancer Center
The Bronx, New York
Duke University Medical Center
Durham, North Carolina
University Hospitals Cleveland Medical Center
Cleveland, Ohio
Local Institution - 104
Greenville, South Carolina
Baylor Sammons Cancer Center
Dallas, Texas
Local Institution - 906
East Melbourne, Australia
Local Institution - 905
Melbourne, Australia
Local Institution - 901
Concord, New South Wales, Australia
Local Institution - 904
Adelaide, South Australia, Australia
Local Institution - 803
Linz, Austria
Local Institution - 811
Yvoir, Belgium
Local Institution - 251
Jaú, Brazil
Local Institution - 253
Rio de Janeiro, Brazil
Local Institution - 254
São Paulo, Brazil
Local Institution - 250
Porto Alegre, Rio Grande do Sul, Brazil
Local Institution - 252
Porto Alegre, RS, Rio Grande do Sul, Brazil
Local Institution - 202
Edmonton, Alberta, Canada
Local Institution - 203
Winnipeg, Manitoba, Canada
Local Institution - 201
Toronto, Ontario, Canada
Local Institution - 204
Montreal, Quebec, Canada
Local Institution - 885
Beijing, China
Local Institution - 884
Beijing, China
Local Institution - 892
Beijing, China
Local Institution - 888
Chengdu, Sichuan, China
Local Institution - 882
Fuzhou, China
Local Institution - 881
Guangzhou, Guangdong, China
Local Institution - 883
Hangzhou, China
Local Institution - 887
Shanghai, China
Local Institution - 891
Shanghai, China
Local Institution - 889
Zhengzhou, China
Local Institution - 822
Prague, Czechia
Local Institution - 834
Aalborg, Denmark
Local Institution - 833
Arhus C, Denmark
Showing 40 of 93 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.